Cloudbreak Reports P-III (CS-301) Topline Data of CBT-001 for Pterygium

Shots: Cloudbreak Pharma has reported topline results from its multi-regional, double-masked, randomized, vehicle-controlled P-III (CS-301) study of CBT-001 ophthalmic emulsion in pts with pterygium (n=659) Both CBT-001 0.1% & 0.2% BID met the 1EPs, showing statistically significant improvement in conjunctival hyperemia at Month 3 vs vehicle (p<0.001; benefit from Week 2 through Month 12) & prevention of pterygium lesion-length progression at Month 12 vs vehicle (p<0.001) Superficial punctate keratitis was the most common AE (20% with 0.1% vs 8% vehicle), mostly resolving with artificial tears; Cloudbreak intends to meet the US FDA to discuss next steps for this potential first disease-modifying pterygium therapy Ref: GlobeNewswire  |   Image: Cloudbreak Pharma  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Cloudbreak Reports P-III (CS-301) Topline Data of CBT-001 for Pterygium appeared first on PharmaShots.